CRDL (Cardiol) Net earnings per share (EPS TTM)

Public company logo of Cardiol (CRDL)

Current partnerships with medical centers combating cardiac inflammation establish a short-term foundation, yet long-term growth is driven by FDA orphan statuses and the final testing stages of Cardiol Therapeutics (CRDL). The rolling year earnings per share (EPS) illustrates this balance, with the metric currently standing at -0.24. An innovative cannabidiol-based pipeline and high R&D efficiency confirm the asset's development potential.

CRDL Cardiol Therapeutics Net earnings per one share for the last twelve months (07/04/2022 - 11/16/2026)

Analytical breakdowns for cardiolrx.com (CRDL)

Summary company analytics:Cardiol (CRDL)
Flagship merchandise of Cardiol Therapeutics

The metric is calculated by dividing the total annual net income by the number of shares outstanding. This metric smooths out quarterly lags, separating the fundamental trend from market noise. For Cardiol Therapeutics (CRDL), which invests in R&D for anti-inflammatory therapy, EPS reflects the cost of developing new formulas. Analyzing the 12-month EPS trend on GURU.Markets allows for an assessment of the efficiency of innovation spending. This chart's price action determines the company's investment attractiveness relative to its competitors.